Pembrolizumab for Previously Untreated Resectable or Borderline Resectable Pancreatic Cancer

IRB/UVA Tracking #
Principal Investigator
Todd W Bauer
Christopher Blackwell
Contact Email
Contact Phone
Official Trial Title
A Randomized Multicenter Phase Ib/II study to assess the safety and the immunological effect of chemoradiation therapy (CRT) in combination with MK-3475 (anti-PD1) to CRT alone in patients with resectable or borderline resectable pancreatic cancer
Study Description

UVA Cancer Center seeks men and women 18 years and older to join a research study to test a new treatment combination for patients with resectable (surgical removal) or borderline resectable pancreatic cancer.

The purpose of this study is to determine whether the study drug, pembrolizumab or MK-3475, can be used safely in combination with chemoradiation in patients with resectable or borderline resectable pancreatic cancer. Patients will be randomized to receive chemoradiation plus pembrolizumab or chemoradiation alone. You may be eligible for this study if you have not received prior treatment for your pancreatic cancer and your doctor recommended that you get treatment to try and shrink your tumor before surgery.

The treatment phase of the study will require 6 visits over 21 weeks. Additional follow-up visits will be scheduled with your regular cancer care and is estimated to add 20-40 minutes to your visit.

If your cancer has spread to other parts of the body, you will not be eligible for this study, however please contact us to be screened for a different study.

For more information, or to see if you qualify to take part in this study, please contact:

Contact: Chris Blackwell
Phone: (434)982-1901


No Compensation